- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06455202
Une étude de phase 3 sur le barzolvolimab chez des participants atteints d'urticaire spontanée chronique (CSU) (EMBARQ-CSU2)
Une étude de phase 3 randomisée, en double aveugle, contrôlée par placebo pour évaluer l'efficacité et l'innocuité du barzolvolimab chez les patients atteints d'urticaire spontanée chronique qui restent symptomatiques malgré un traitement antihistaminique H1 (EMBARQ-CSU2)
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a global, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study investigating the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who are symptomatic despite treatment with non-sedating second generation H1-antihistamines at 1-4 times the locally approved dose.
There is a screening period of up to 4 weeks, followed by a 24-week placebo-controlled treatment period, a 28-week active treatment period where all participants receive barzolvolimab followed by a 16-week treatment free period.
Approximately 915 adult participants (610 in the active arms and 305 in the placebo arm) will be randomly assigned to the treatment arms.
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Aachen, Allemagne, 52074
- Universitätsklinikum der RWTH Aachen Hautklinik
-
Bad Bentheim, Allemagne, 48455
- Fachklinik Bad Bentheim
-
Berlin, Allemagne, 10629
- Emovis GmbH
-
Bonn, Allemagne, 53127
- Universitätsklinikum Bonn
-
Dresden, Allemagne, 01307
- Universitätsklinikum Carl Gustav Carus an der TU Dresden
-
Düsseldorf, Allemagne, 40225
- Universitätsklinikum Düsseldorf
-
Essen, Allemagne, 45147
- Universitätsklinikum Essen
-
Hamburg, Allemagne, 20095
- Eurofins bioskin Research Center Dermalology
-
Lübeck, Allemagne, 23538
- UKSH Lübeck, Institut für Entzündungsmedizin
-
Mannheim, Allemagne, 68167
- Universitätsklinikum Mannheim
-
Münster, Allemagne, 48149
- Universitätsklinikum Münster
-
Remscheid, Allemagne, 42897
- Hautarztpraxis Dariusch Mortazawi
-
Tübingen, Allemagne, 72076
- Universitäts-Hautklinik, Studienzentrum Immundermatologie
-
-
-
-
New South Wales
-
Charlestown, New South Wales, Australie, 2290
- Novatrials
-
Darlinghurst, New South Wales, Australie, 2010
- Skin and Cancer Foundation - The Skin Hospital
-
Kogarah, New South Wales, Australie, 2217
- St George Dermatology and Skin Cancer Center
-
Westmead, New South Wales, Australie, 2145
- Westmead Hospital
-
-
Queensland
-
Brisbane, Queensland, Australie, 4102
- Princess Alexandra Hospital
-
Coorparoo, Queensland, Australie, 4151
- Cornerstone Dermatology
-
Woolloongabba, Queensland, Australie, 4102
- Veracity Clinical Research Pty Ltd
-
-
Victoria
-
Box Hill, Victoria, Australie, 3128
- Box Hill Hospital
-
East Melbourne, Victoria, Australie, 3002
- Dr Rodney Sinclair Pty Ltd
-
Melbourne, Victoria, Australie, 3004
- The Alfred Hospital
-
Parkville, Victoria, Australie, 3050
- The Royal Melbourne Hospital
-
-
-
-
-
Dupnitsa, Bulgarie, 2600
- Medical Centre Asklepii OOD
-
Haskovo, Bulgarie, 6300
- Medical Center - Pulmo 2018
-
Lovech, Bulgarie, 5500
- Medical Center Medconsult Pleven
-
Pazardzhik, Bulgarie, 4400
- Multiprofile Hospital for Active Treatment - Pazardzhik AD
-
Plovdiv, Bulgarie, 4002
- University Multiprofile Hospital for Active Treatment Sveti Georgi EAD
-
Rousse, Bulgarie, 7000
- Medical Center Prolet
-
Sevlievo, Bulgarie, 5400
- Medical Center Unimed EOOD
-
Sofia, Bulgarie, 1431
- University Multiprofile Hospital for Active Treatment Aleksandrovska EAD
-
Sofia, Bulgarie, 1527
- University Multiprofile Hospital for Active Treatment "Tsaritsa Yoanna - ISUL"
-
Sofia, Bulgarie, 1431
- Diagnostic and Consultative Center Aleksandrovska EOOD
-
Sofia, Bulgarie, 1680
- Diagnostic-Consultative Centre Convex EOOD
-
Sofia, Bulgarie, 1202
- Diagnostic-consultative center Ascendent EOOD
-
-
-
-
-
Kingston, Canada, K7L 2V7
- Kingston Health Science Center
-
Québec, Canada, G1W4R4
- Centre de Recherche Saint-Louis (Québec)
-
-
Alberta
-
Edmonton, Alberta, Canada, T5J 3S9
- Laser Rejuvenation Clinics Edmonton D.T. Inc.
-
Edmonton, Alberta, Canada, T6H 4J8
- Vida Clinical Research
-
Edmonton, Alberta, Canada, T6W 0J5
- Rejuvenation Dermatology Edmonton South
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 3C3
- LEADER research
-
London, Ontario, Canada, N6H 5L5
- DermEffects
-
North Bay, Ontario, Canada, P1B 3Z7
- North Bay Dermatology Centre
-
Ottawa, Ontario, Canada, K1H1E4
- Ottawa Allergy Research Corporation
-
Richmond Hill, Ontario, Canada, L4B 1L1
- York Dermatology Clinic & Research Centre
-
Toronto, Ontario, Canada, M2N 3A6
- North York Research Inc.
-
Windsor, Ontario, Canada, N8X 2G1
- Joel Liem Medicine Professional Corporation
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7T0G3
- Saskatoon Dermatology Centre
-
-
-
-
-
Lo Barnechea, Chili, 7691236
- Clinica MEDS La Dehesa
-
Osorno, Chili, 5290000
- Hospital Base San Jose de Osorno
-
Providencia, Chili, 7500000
- Enroll SpA - Dr. Manuel Barros Borgono
-
Recoleta, Chili, 8420000
- Clinica Davila - Recoleta
-
Recoleta, Chili, 8420383
- Centro Internacional de Estudios Clinicos (CIEC)
-
Santiago, Chili, 8350595
- BIOCINETIC Ltda
-
Vitacura, Chili, 7630000
- Dermacross Clinica Dermatologica
-
Viña del Mar, Chili, 2520000
- Medical Skin Center
-
-
-
-
-
Barranquilla, Colombie, 8001
- Centro Integral de Reumatologia Del Caribe
-
Medellín, Colombie, 50012
- Centro de Inmunología y Genética - CIGE S.A.S
-
Medellín, Colombie, 50015
- Hospital General de Medellín Luz Castro de Gutiérrez
-
Medellín, Colombie, 50021
- Fundación Centro de Investigation Clínica CIC
-
Medellín, Colombie, 50010
- Hospital Alma Mater de Antioquia
-
Soledad, Colombie, 83001
- Fundación Hospital Universidad del Norte
-
-
-
-
-
Rijeka, Croatie, 51000
- Special Hospital Medico
-
Zagreb, Croatie, 10000
- Solmed Clinic
-
-
-
-
-
Barcelona, Espagne, 08003
- Hospital del Mar
-
Cadiz, Espagne, 11009
- Hospital Universitari Puerta del Mar
-
Madrid, Espagne, 28006
- Hospital Universitario de La Princesa
-
Madrid, Espagne, 28041
- Hospital 12 De Octubre
-
Pamplona, Espagne, 31008
- Clinica Universidad Navarra- Pamplona
-
Pozuelo de Alarcón, Espagne, 28223
- Hospital Quironsalud Madrid
-
Seville, Espagne, 41012
- FutureMeds Sevilla
-
Seville, Espagne, 41009
- Hospital universitario Virgen Macarena
-
Torrejón de Ardoz, Espagne, 28850
- Hospital Universitario de Torrejón
-
Valencia, Espagne, 46026
- Hospital Universitari i Politecnic La Fe de Valencia
-
Valencia, Espagne, 46940
- Hospital de Manises
-
-
-
-
-
Tbilisi, Géorgie, 0119
- LTD" Healthy Future"
-
Tbilisi, Géorgie, 0159
- LTD "Center of Allergy and Immunology"
-
Tbilisi, Géorgie, 0179
- David Abuladze Georgian Italian Clinic
-
Tbilisi, Géorgie, 0186
- LTD "Multiprofile Clinic Consilium Medulla"
-
-
-
-
-
Debrecen, Hongrie, 4032
- Debreceni Egyetem Klinikai Kozpont Nagyerdei Campus
-
Szeged, Hongrie, 6725
- Szent-Gyorgyi Albert Klinikai Kozpont
-
Szolnok, Hongrie, 5000
- Allergo-Derm Bakos Kft.
-
-
-
-
-
Ahmedabad, Inde, 380005
- Panchshil Hospital - Ahmedabad
-
Ahmedabad, Inde, 380016
- B. J. Medical College and Civil Hospital
-
Belagavi, Inde, 590010
- KLES Dr Prabhakar Kore Hospital & Medical Research Centre
-
Bhubaneswar, Inde, 751019
- All India Institute of Medical Sciences
-
Jaipur, Inde, 302017
- Apex Hospitals Pvt Ltd
-
Mysore, Inde, 570001
- K R Hospital
-
Pune, Inde, 411004
- Deenanath Mangeshkar Hospital and Research Centre
-
Vadodara, Inde, 391760
- Sumandeep Vidyapeeth University - Dhiraj Hospital
-
-
Gujarat
-
Surat, Gujarat, Inde, 395002
- Nirmal Hospital PVT LTD
-
Vadodara, Gujarat, Inde, 390001
- Medical College Baroda & SSG Hospital
-
-
Maharashtra
-
Nagpur, Maharashtra, Inde, 440009
- Shree Hospital & Critical Care Centre
-
Nashik, Maharashtra, Inde, 422101
- Assured Care Plus Hospital
-
Pune, Maharashtra, Inde, 411005
- Oyster & Pearl Hospitals
-
-
Rajasthan
-
Jaipur, Rajasthan, Inde, 302012
- Excelcare Hospital
-
-
Uttar Pradesh
-
Kanpur, Uttar Pradesh, Inde, 208002
- G.S.V.M. Medical College - Kanpur
-
-
-
-
-
Genova, Italie, 16132
- IRCCS Ospedale Policlinico San Martino
-
Milan, Italie, 20157
- Asst Fbf Sacco
-
Padova, Italie, 38068
- Azienda Ospedale Università di Padova
-
Rozzano, Italie, 20089
- Humanitas Research Hospital
-
Salerno, Italie, 84131
- AOU San Giovanni di Dio e Ruggi d'Aragona
-
San Donato Milanese, Italie, 20097
- IRCCS Policlinico San Donato
-
Torino, Italie, 10126
- Ospedale San Lazzaro PO Molinette
-
-
-
-
-
Kaunas, Lituanie, LT-44192
- CD8 Klinika
-
Kaunas, Lituanie, LT-49387
- UAB Ausros Medicinos Centras
-
Vilnius, Lituanie, LT-08109
- UAB "Alerginių susirgimų diagnostikos ir gydymo centras"
-
Vilnius, Lituanie, LT-08406
- Santaros KTC (klinikiniu tyrimu centras)
-
-
-
-
-
Chihuahua City, Mexique, 31200
- Unidad de Investigación Cima S.a
-
Chihuahua City, Mexique, 31203
- Meidadvance Clinical
-
Cuauhtémoc, Mexique, 06100
- Cryptex
-
Guadalajara, Mexique, 44130
- Centro de Investigación Medico Biologica
-
Guadalajara, Mexique, 44340
- CIMET
-
Guadalajara, Mexique, 44670
- Panamerican Guadalajara
-
Monterrey, Mexique, 64718
- Eukarya Pharmasite
-
Morelia, Mexique, 58249
- CECYPE
-
Mérida, Mexique, 97000
- Centro de Desarrollo Biomédico
-
Mérida, Mexique, 97125
- Mérida Investigación Clínica
-
San Juan del Río, Mexique, 76800
- Unidad de Medicina Especializada
-
Veracruz, Mexique, 91900
- FAICIC
-
-
-
-
-
Auckland, Nouvelle-Zélande, 1010
- Optimal Clinical Trials - Central
-
Christchurch, Nouvelle-Zélande, 8013
- Pcrn Chch
-
Dunedin, Nouvelle-Zélande, 9016
- Momentum Clinical Research Dunedin
-
Hamilton, Nouvelle-Zélande, 3200
- Lakeland Clinical Trials - Waikato
-
Nelson, Nouvelle-Zélande, 7011
- velocity Nova Sp. z o.o.
-
Rotorua, Nouvelle-Zélande, 3010
- Pacific Clinical Research Network Rotorua
-
Tauranga, Nouvelle-Zélande, 3110
- Momentum Clinical Research Tauranga
-
Upper Hutt, Nouvelle-Zélande, 5018
- Lakeland Clinical Trials Wellington
-
-
-
-
-
Amsterdam, Pays-Bas, 1105 AZ
- AmdsterdamUMC locatie AMC
-
Roosendaal, Pays-Bas, 4708 AE
- Bravis Hospital
-
Utrecht, Pays-Bas, 3584 CX
- University Medical Center Utrecht
-
-
-
-
-
Częstochowa, Pologne, 42-217
- Centrum Medyczne Pratia Częstochowa
-
Częstochowa, Pologne, 42-202
- Klinika Dermatologii i Dermatologii Onkologicznej
-
Elblag, Pologne, 82-300
- Centrum Kliniczno-Badawcze J.Brzezicki,B.Górnikiewicz-Brzezicka, Lekarze Spółka Partnerska
-
Gdansk, Pologne, 80-382
- Synexus Polska Sp. z o.o.
-
Grodzisk Mazowiecki, Pologne, 05-825
- Mazowieckie Centrum Badań Klinicznych SC IWONA CZAJKOWSKA ANNA PODRAZKA-SZCZEAPANIAK
-
Katowice, Pologne, 40-611
- Provita Sp zoo
-
Krakow, Pologne, 30-363
- Centrum Medyczne Plejady
-
Krakow, Pologne, 31-624
- Malopolskie Centrum Alergologii
-
Krakow, Pologne, 30-033
- Centrum Medyczne "All-Med" Badania Kliniczne
-
Lodz, Pologne, 92-213
- Uniwersytet Medyczny w Łodzi - Centrum Wsparcia Badań Klinicznych
-
Lublin, Pologne, 20-362
- Velocity Nova Sp. z o.o.
-
Lublin, Pologne, 20-607
- DERMEDIC Iwona Zdybska
-
Lublin, Pologne, 20-412
- Pro Life Medica ETG Lublin
-
Lublin, Pologne, 20-753
- LUXDERM Specjalistyczny Gabinet Dermatologiczny Prof. dr hab. n. med. Dorota Krasowska
-
Nowa Sól, Pologne, 67-100
- Twoja Przychodnia Nowosolskie Centrum Medyczne
-
Opole, Pologne, 45-401
- Uniwersytecki Szpital Kliniczny w Opolu
-
Oświęcim, Pologne, 32-600
- Medicome Sp. Z O.O.
-
Poznan, Pologne, 60-214
- Centrum Alergologii Teresa Hofman Sp. z.o.o.
-
Poznan, Pologne, 60-309
- EMC Instytut Medyczny SA, PL Certus Szpital i Ambulatorium
-
Poznan, Pologne, 60-693
- Specjalistyczny Niepubliczny Zaklad Opieki Zdrowotnej Alergologia Plus Osrodek Diagnostyki I Terapii Uczulen
-
Rzeszów, Pologne, 35-055
- Uniwersytecki Szpital Kliniczny im. Fryderka Chopina w Rzeszowie Klinika Dermatologii i Dermatologii Onkologicznej
-
Rzeszów, Pologne, 35-205
- EMED Centrum Usług Medycznych Ewa Śmiałek
-
Tarnów, Pologne, 33-100
- ALERGO-MED SPECJALISTYCZNA PRZYCHODNIA LEKARSKA Spolka. z o. o.
-
Warsaw, Pologne, 02-677
- ETG Warszawa
-
Warsaw, Pologne, 02-672
- Synexus Polska Sp. z o.o.
-
Warsaw, Pologne, 00-874
- Medicover Integrated Clinical Services Sp. z o.o. Centrum Medyczne Warszawa
-
-
-
-
-
Bristol, Royaume-Uni, BS10 5NB
- Southmead Hospital
-
Cambridge, Royaume-Uni, CB2 0QQ
- Cambridge University Hospitals, Addenbrooke's Hospital
-
Edinburgh, Royaume-Uni, EH4 2XU
- Western General Hospital
-
Glasgow, Royaume-Uni, G51 4TF
- Queen Elizabeth University Hospital
-
High Wycombe, Royaume-Uni, HP11 2QW
- Velocity Clinical Research High Wycombe
-
Leeds, Royaume-Uni, LS9 7TF
- St James's University Hospital
-
London, Royaume-Uni, E1 1FR
- The Royal London Hospital
-
North Finchley, Royaume-Uni, N12 8BU
- Velocity Clinical Research, North London - PPDS
-
Oxford, Royaume-Uni, OX44 9PU
- Virtual Clinical Trials Centre, The Stables
-
Plymouth, Royaume-Uni, PL6 5FP
- University Hospitals Plymouth NHS Trust
-
Reading, Royaume-Uni, RG1 5AN
- Royal Berkshire Hospital
-
Romford, Royaume-Uni, RM1 3PJ
- Velocity Clinical Research - Romford
-
Wakefield, Royaume-Uni, WF1 4DG
- Pinderfields Hospital
-
-
-
-
-
Bardejov, Slovaquie, 08501
- MAXDERM s.r.o.
-
Bratislava, Slovaquie, 85101
- Derma therapy spol. s.r.o.
-
Košice, Slovaquie, 04022
- ALERSA, sro
-
Trnava, Slovaquie, 91702
- Fakultna nemocnica Trnava
-
-
-
-
-
Bangkok Noi, Thaïlande, 10700
- Siriraj Hospital
-
Chiang Mai, Thaïlande, 50200
- Maharaj Nakorn Chiang Mai Hospital
-
Khlong Luang, Thaïlande, 12120
- Thammasat University Hospital
-
Khon Kaen, Thaïlande, 40002
- Khon Kaen University
-
-
-
-
-
Sfax, Tunisie, 3029
- Hôpital Hédi Chaker
-
Tunis, Tunisie, 1007
- La Rabta Hospital
-
Tunis, Tunisie, 1008
- Habib Thameur Hospital
-
-
-
-
Alabama
-
Cullman, Alabama, États-Unis, 35058
- Allervie Clinical Research - Cullman
-
-
Arizona
-
Litchfield Park, Arizona, États-Unis, 85340
- Research Solutions of Arizona PC
-
Scottsdale, Arizona, États-Unis, 85258
- Medical Research of Arizona a division of Allergy, Asthma, & Immunology, Assoc. Ltd.
-
Scottsdale, Arizona, États-Unis, 85260
- Center for Dermatology & Plastic Surgery
-
-
California
-
Bakersfield, California, États-Unis, 93301
- Kern Research, Inc.
-
Los Angeles, California, États-Unis, 90057
- LA Universal Research Center, Inc.
-
Los Angeles, California, États-Unis, 90025
- California Allergy and Asthma Medical Group
-
Los Angeles, California, États-Unis, 90024
- UCLA Clinical Trials Contracts & Strategic Relations
-
Mission Viejo, California, États-Unis, 92691
- Allergy and Asthma Associates of Southern Cal
-
Pasadena, California, États-Unis, 91107
- Huntington Asthma & Allergy Center
-
San Diego, California, États-Unis, 92123
- University Clinical Trials
-
San Diego, California, États-Unis, 92120
- WR-MCCR
-
San Diego, California, États-Unis, 92120
- Apex Clinical Research
-
Santa Monica, California, États-Unis, 90404
- Clinical Science Institute
-
Santa Monica, California, États-Unis, 90404
- Raffi Tachdjian MD, Inc
-
-
Colorado
-
Castle Rock, Colorado, États-Unis, 80109
- Clarity Dermatology, PLLC
-
Colorado Springs, Colorado, États-Unis, 80907
- Asthma and Allergy Associates
-
-
Florida
-
Coral Gables, Florida, États-Unis, 33134
- Driven Research LLC
-
Delray Beach, Florida, États-Unis, 33484
- Palm Beach Dermatology Group
-
Doral, Florida, États-Unis, 33172
- Dolphin Medical Research
-
Miami, Florida, États-Unis, 33165
- South FL Clinical Research LLC
-
Miami, Florida, États-Unis, 33173
- Dade Florida Clinical Research Center
-
Miami Lakes, Florida, États-Unis, 33014
- Deluxe Health Center
-
Orlando, Florida, États-Unis, 32807
- Revival Clinical Research
-
Sanford, Florida, États-Unis, 32771
- International Clinical Research - FL LLC
-
Tamarac, Florida, États-Unis, 33321
- D&H Tamarac Research Center, LLC
-
Tampa, Florida, États-Unis, 33613
- University of South Florida
-
Tampa, Florida, États-Unis, 33615
- Olympian Clinical Research
-
Tampa, Florida, États-Unis, 33609
- MOORE Clinical Research, Inc. d/b/a TrueBlue Clinical Research
-
Tampa, Florida, États-Unis, 33607
- Advanced Clinical Research Institute (ACRI) - Florida
-
Tampa, Florida, États-Unis, 33607
- Deluxe Health Center
-
-
Georgia
-
Columbus, Georgia, États-Unis, 31904
- Lane Dermatology Research - Centricity - PPDS
-
Macon, Georgia, États-Unis, 31217
- Skin Care Physicians of Georgia
-
-
Idaho
-
Boise, Idaho, États-Unis, 83706
- Treasure Valley Medical Research
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60612
- Rush University Medical Center
-
Normal, Illinois, États-Unis, 61761
- Sneeze Wheeze and Itch Associates LLC
-
-
Indiana
-
Plainfield, Indiana, États-Unis, 46168
- The Indiana Clinical Trials Center, PC
-
South Bend, Indiana, États-Unis, 46617
- South Bend Clinic
-
-
Kansas
-
Kansas City, Kansas, États-Unis, 66160-8500
- University of Kansas Medical Center
-
-
Kentucky
-
Bowling Green, Kentucky, États-Unis, 42104
- Equity Medical
-
Lexington, Kentucky, États-Unis, 40509
- Allergy & Asthma Associates
-
-
Louisiana
-
Baton Rouge, Louisiana, États-Unis, 70808
- Velocity Clinical Research - The Dermatology Clinic - Baton Rouge - PPDS
-
-
Maryland
-
Towson, Maryland, États-Unis, 21204
- Continental Clinical Research Solutions, LLC - ClinEdge - PPDS
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Brigham and Women's Hospital
-
-
Michigan
-
Caledonia, Michigan, États-Unis, 49316
- Derm Institute of Western Michigan
-
Clarkston, Michigan, États-Unis, 48346
- Clarkston Skin Research - Clarkston
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63141
- Washington University School of Medicine
-
St Louis, Missouri, États-Unis, 63141
- Midwest Clinical Research, LLC
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68144
- Skin Specialists PC
-
-
New Jersey
-
Belleville, New Jersey, États-Unis, 07109
- Hudson-Essex Allergy
-
Paramus, New Jersey, États-Unis, 07652
- Impact Medical / Circuit Clinical
-
Riverdale, New Jersey, États-Unis, 07457
- Impact Medical / Circuit Clinical
-
-
New York
-
New York, New York, États-Unis, 10128
- OptiSkin Medical
-
New York, New York, États-Unis, 10023
- Equity Medical LLC
-
-
Ohio
-
Boardman, Ohio, États-Unis, 44512
- Optima Research
-
Columbus, Ohio, États-Unis, 43235
- Optimed Research Ltd - ClinEdge - PPDS
-
-
Pennsylvania
-
Hershey, Pennsylvania, États-Unis, 17033
- Penn State Health Milton Hershey Med Cen
-
-
Rhode Island
-
Johnston, Rhode Island, États-Unis, 02919
- Clinical Partners LLC
-
-
Texas
-
El Paso, Texas, États-Unis, 79932
- Western Sky Medical Research
-
Pflugerville, Texas, États-Unis, 78660
- Austin Institute for Clinical Research, Inc.
-
San Antonio, Texas, États-Unis, 78213
- Rainey & Finklea San Antonio Dermatology
-
-
Utah
-
Murray, Utah, États-Unis, 84107
- Allergy Associates of Utah - Sandy
-
West Valley City, Utah, États-Unis, 84120
- Kalo Clinical Research
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key Inclusion Criteria:
-
Males and females, >/= 18 years of age.
-
Chronic spontaneous urticaria (CSU) >/= 6 months prior to Screening (Visit 1).
-
CSU despite the use of a stable regimen of second generation non-sedating H1-antihistamine as defined by:
- The presence of hives for >/= 6 weeks at any time prior to Visit 1 despite the use of non-sedating H1-antihistamines.
- Must be on a stable regimen of second generation non-sedating H1-antihistamine for >/= 4 weeks prior to study treatment.
- UAS7 of >/= 16 and ISS7 of >/= 8 during the 7 days prior to study treatment.
-
Normal blood counts and liver function tests.
-
Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days after treatment.
-
Willing and able to complete a daily symptom electronic diary and comply with study visits.
-
Participants with and without prior biologic experience are eligible.
Key Exclusion Criteria:
- Women who are pregnant or nursing.
- Chronic urticaria whose predominant manifestation is due to CIndU.
- Other diseases associated with urticaria.
- Active pruritic skin condition in addition to CSU.
- Medical condition that would cause additional risk or interfere with study procedures.
- Known HIV, hepatitis B or hepatitis C infection.
- Vaccination of a live vaccine within 30 days prior to Screening (Visit 1) (subjects must agree to avoid live vaccinations during the study). Inactivated vaccines are allowed such as seasonal influenza injection or authorized COVID-19 vaccine.
- History of anaphylaxis
- Prior treatment with barzolvolimab
There are additional criteria that your study doctor will review with you to confirm you are eligible for the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: barzolvolimab 150 mg
barzolvolimab given once as a 300 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 52 weeks |
Subcutaneous Administration |
|
Expérimental: barzolvolimab 300 mg
barzolvolimab given once as a 450 mg subcutaneous injection followed by 300 mg administered every 8 weeks for 52 weeks |
Subcutaneous Administration |
|
Expérimental: Placebo then barzolvolimab 150 mg
Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 300 mg followed by 150 mg administered every 4 weeks for 28 weeks. |
Subcutaneous Administration Matching placebo Subcutaneous Administration |
|
Expérimental: Placebo then barzolvolimab 300 mg
Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 450 mg followed by 300 mg administered every 8 weeks for 28 weeks. |
Subcutaneous Administration Matching placebo Subcutaneous Administration |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score)
Délai: From Day 1 (first dose) to Day 85 (Week 12)
|
Evaluate efficacy of barzolvolimab on urticaria activity as measured by urticaria activity score (UAS). The UAS7 is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42, and a minimum possible score of 0. |
From Day 1 (first dose) to Day 85 (Week 12)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Mean change from baseline to Week 12 of ISS7 (Itch Severity Score)
Délai: From Day 1 (first dose) to Day 85 (Week 12)
|
The ISS7 and HSS7 combined together make up the UAS7 scoring system to evaluate urticaria signs and symptoms. The ISS7 is the itch severity score for 7 days, the scores range from 0 to 21. |
From Day 1 (first dose) to Day 85 (Week 12)
|
|
Mean change from baseline to Week 12 of HSS7 (Hives Severity Score)
Délai: From Day 1 (first dose) to Day 85 (Week 12)
|
The ISS7 and HSS7 combined together make up the UAS7 scoring system to evaluate urticaria signs and symptoms. The HSS7 score is the wheal/hives severity score for 7 days, the scores range from 0 to 21. |
From Day 1 (first dose) to Day 85 (Week 12)
|
|
Percentage of participants with UAS7 ≤ 6 at Week 12
Délai: From Day 1 (first dose) to Day 85 (Week 12)
|
Proportion of participants who achieve control of their urticaria signs and symptoms (UAS7≤6) at Week 12. |
From Day 1 (first dose) to Day 85 (Week 12)
|
|
Percentage of participants with AAS7 > 0 at baseline with AAS7 = 0 at Week 12
Délai: From Day 1 (first dose) to Day 85 (Week 12)
|
Proportion of participants with AAS7 > 0 at Day 1 who achieved complete control (AAS7 = 0) at Week 12 Angioedema Activity Score over 7 days [AAS7] describes the effect of angioedema on five categories with 0 being none and 3 being most severe. The final score is calculated by adding together daily scores which can range from 0-15 for 7 days. The resulting maximum score is then 105. |
From Day 1 (first dose) to Day 85 (Week 12)
|
|
Mean change from baseline in UAS7 in participants refractory to omalizumab treatment at Week 12
Délai: From Day 1 (first dose) to Day 85 (Week 12)
|
Evaluate efficacy of barzolvolimab on urticaria activity as measured by urticaria activity score (UAS) in participants who did not respond to or did not tolerate omalizumab. The UAS7 is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42, and a minimum possible score of 0. |
From Day 1 (first dose) to Day 85 (Week 12)
|
|
Proportion of participants with UAS7 = 0 in participants refractory to omalizumab treatment at Week 12
Délai: From Day 1 (first dose) to Day 85 (Week 12)
|
Proportion of participants who achieve complete absence of hives and itch (UAS7 = 0) at Week 12 in participants who did not respond to or did not tolerate omalizumab. |
From Day 1 (first dose) to Day 85 (Week 12)
|
|
Incidence of Treatment-Emergent Adverse Events
Délai: From Day 1 (first dose) to Day 477 (Week 68)
|
Occurrence of treatment emergent adverse events and serious adverse events during the study. |
From Day 1 (first dose) to Day 477 (Week 68)
|
|
Percentage of patients with UAS7=0 at Week 12
Délai: From Day 1 (first dose) to Day 85 (Week 12)
|
Proportion of participants who achieve complete absence of hives and itch (UAS7 = 0) at Week 12. |
From Day 1 (first dose) to Day 85 (Week 12)
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Maladie chronique
- Attributs de la maladie
- Maladies du système immunitaire
- Hypersensibilité immédiate
- Hypersensibilité
- Maladies de la peau
- Urticaire
- Maladies de la peau, vasculaire
- Conditions pathologiques, signes et symptômes
- Maladies de la peau et du tissu conjonctif
- Urticaire chronique
Autres numéros d'identification d'étude
- CDX0159-13
- 2024-513210-36-00 (Ctis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .